ReviewFrontiers in oncology2025
Meta-analysis of the efficacy and safety of Kanglaite Injection in conjunction with chemotherapy for cancer pain.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically assess the clinical efficacy and safety of Kanglaite Injection in combination with chemotherapy for cancer pain. Using PICO framework: Population (adult cancer patients with pain), Intervention (Kanglaite Injection + chemotherapy), Comparator (chemotherapy alone), Outcomes (pain scores, relief rates, KPS, adverse events). Methods: The CNKI, WanFang, VIP, Chinese Biomedical Database, PubMed, Embase and Cochrane Library databases were systematically searched. Randomized controlled trials specifically investigating the combined use of Kanglaite Injection and chemotherapy for cancer pain were included from the inception of the database until October 14, 2025. Literature screening and quality assessment were independently conducted by two researchers, with cross-verification. The extracted data were meta-analyzed using Rev Man 5.3 software. Results: A total of 18 randomized controlled trials involving 1197 patients were included. The combined analysis demonstrated that Kanglaite Injection in conjunction with chemotherapy showed significant advantages over chemotherapy alone in terms of pain intensity score [SMD=-1.24, 95% CI (-1.68, -0.80), P<0.001], pain relief rate [RR = 1.72, 95% CI (1.52, 1.95), P<0.001], and enhancement in the Karnofsky Performance Status (KPS) score improvement rate [RR = 1.64, 95% CI (1.39, 1.93), P<0.001]. Furthermore, Kanglaite Injection combined with chemotherapy exhibited advantages in reducing post-chemotherapy gastrointestinal reactions [RR = 0.68, 95% CI (0.57, 0.81), P<0.001], white blood cell reduction [RR = 0.73, 95% CI (0.57, 0.93), P<0.001], and liver function damage [RR = 0.45, 95% CI (0.27, 0.75), P<0.001]. Evidence certainty was moderate for most outcomes per GRADE assessment. Conclusion: The combination of Kanglaite Injection with chemotherapy appears effective and safe in treating cancer pain based on moderate-certainty evidence, pending further high-quality trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.